About OtsukaTimeline of Otsuka's History
- PhPharmaceutical business
- NCNutraceutical business
BeanStalk Kids Center OSAKA opened
Opened as Otsuka Pharmaceutical's first in-house child care center in Tokushima
Otsuka Pharmaceutical was awarded “Diversity Management Selection 100” from the Japan Ministry of Economy, Trade and Industry
Samsca introduced in Japan for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Vasopressin V2-receptor antagonist
Strategic alliance with IBM in the Central Nervous System (CNS) field
DELTYBA launched in Europe and Japan
Treatment for multidrug-resistant tuberculosis (MDR-TB)
NUEDEXTA launched in U.S.
Pseudobulbar affect (PBA)
Milical launched in Japan
Milical sold in Japan is imported from France-based Nutrition et Santé
Brazil-based Jasmine joined group
Calorie Mate recognized with Good Design Long Life Design Award 2014
Tatsuo Higuchi appointed president and representative director of Otsuka Pharmaceutical Co. Ltd. in addition to existing role as president, representative director and CEO of Otsuka Holdings
U.S.-based Avanir Pharmaceuticals, Inc. joined group
Abilify Maintena launched
Otsuka Australia Pharmaceutical Pty Ltd Opens in Australia
Otsuka Pharmaceutical opens its first office in Australia, furthering the company's aim of bringing innovative new treatments to patients in Oceania.
REXULTI launched in the U.S.
Adjunctive treatment for adults with major depressive disorder and as a treatment for adults with schizophrenia.
U.S.-based FoodState joined group
ORONAMIN C DRINK began production and sales in South Korea
ORONAMIN C DRINK marks its 50th Anniversary in Japan
ORONAMIN C DRINK began sales in Hong Kong
Kenja-no-shokutaku Double Support launched in Hong Kong
Otsuka Pharmaceutical subsidiary Nutrition & Santé (N&S) acquired BIOCENTURY, a leading Spanish health and functional foods company
Donated funds for a Rural Health Center in Myanmar
The facility aims to provide stable maternal and child health services including promotion of midwife-assisted childbirth and health education for local residents.
Otsuka Joins UN Global Compact (UNGC)*
Otsuka Holdings Co., Ltd. became a signatory to the United Nations Global Compact (UNGC) in order to express its commitment to corporate social responsibility (CSR) and sustainability.
- The Global Compact is an encouragement for companies to pursue sustainable growth and be a good member of society.
Otsuka's U.S. subsidiary Astex Pharmaceuticals, Inc., enters into a clinical collaboration with Genentech.
Clinical trial collaboration in the treatment of acute myeloid leukemia.
Oraltag™ launched in the U.S.
Oral contrast agent for abdominal CT scans
RIKEN CDB-Otsuka Pharmaceutical Collaboration Center launched in Kobe, Japan.
ICLUSIG® Tablets 15 mg launched in Japan
Drug for chronic myeloidlLeukemia and Philadelphia postive acute lymphoblastic leukemia
Otsuka signed Japan-exclusive license agreement with Takara Bio
License agreement for the investigational cancer treatment HF10, an Oncolytic Virus
Otsuka Pharmaceutical and Akebia Therapeutics, Inc. entered into a collaboration to develop and commercialize Vadadustat in the U.S.
License agreement for vadadustat, an oral hypoxia-inducible factor (HIF) stabilizer, treatment of anemia associated with chronic kidney disease (CKD).
Otsuka Pharmaceutical forms joint venture company for functional food and beverages in the Philippines
SOYJOY Crispy launched in Japan
Soy bar with the pleasant crunchy texture of puffed soy
POCARI SWEAT and ORONAMIN C DRINK recognized with Good Design Long Life Design Award 2016
Otsuka certified as Health & Productivity Management Outstanding Organization
The Health & Productivity Management Outstanding Organizations Recognition Program was jointly instituted by the Ministry of Economy, Trade and Industry (METI) and Nippon Kenko Kaigi. The program certifies legal entities such as companies that implement quality management practices for ensuring a healthy workforce.
Otsuka receives "Sports Yell Company"Certification* from Japan Sports Agency
- Certification is granted to corporations that actively implement policies encouraging participation in sports to promote employee health.
Mikeluna® combination ophthalmic solution launched in Japan
Drug for glaucoma and ocular hypertension
Health Canada Approves Otsuka and Lundbeck's REXULTI®
(brexpiprazole) as a treatment for schizophrenia in adults Antipsychotic drug
Otsuka Pharmaceutical acquired Neurovance, Inc., a U.S. privately held, venture-funded, clinical stage pharmaceutical company.
Aiming to widen Otsuka's presence in mental health
Otsuka and Akebia Concludes Licensing Agreement for Akebia's Renal Anemia Drug Vadadustat
Development and marketing territories include Europe, China, etc.
Otsuka and Teva Sign Licensing Agreement for Japan on Prophylactic Migraine Drug Candidate Fremanezumab (TEV-48125)
Otsuka to Continue Commitment to Support the Global Health Innovative Technology Fund (GHIT Fund)
Quick NaviTM-Mycoplasma Diagnostic Kit to Launch in Japan
Excellent sensitivity and specificity to mycoplasma antigen
Otsuka and R-Pharm Announce Licensing Agreement to Commercialize Deltyba™ (Delamanid) for Multidrug-Resistant Tuberculosis (MDR-TB) in Russia and CIS Countries
"Quick Navi-Flu2" Influenza Diagnostic Kit to Launch in Japan
Flu influenza diagnostic kit
Otsuka and Mylan Announce License Agreement to Commercialize Delamanid (Deltyba™) forMultidrug-Resistant Tuberculosis (MDR-TB) in High-Burden Countries
Otsuka and DKSH to commence sales of Otsuka prescription drugs in Myanmar
Introduced BODYMAINTÉ Brand with the conditioning food BODYMAINTÉ Jelly
BODYMAINTÉ Jelly, a conditioning food to support athletic performance
Otsuka established a new functional food and beverage affiliate"Otsuka Nutraceutical (Thailand) Ltd." in Thailand
Otsuka acquired Daiya, a rapidly growing plant-based food company in North America
EQUELLE launched in US
to contribute to women's health in the US
Otsuka Certified for Two Years in a Row as Health & Productivity Management Outstanding Organization
Otsuka Pharmaceutical established subsidiary in Singapore
REXULTI® Tablets launched in Japan
JYNARQUE™ approved by U.S. FDA as the first treatment to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD)
Vasopressin V2-receptor antagonist
Otsuka acquired Visterra
Visterra's exceptional antibody platform technology joined up with Otsuka
Subsidiary of Otsuka, Nutrition & Santé acquired BC BIO, a French manufacturer of organic food products
Kenja-no-Kaimin Sleep Rhythm Support was available throughout Japan
Kenja-no-Kaimin Sleep Rhythm Support, the food with Function Claim from the Consumer Affairs Agency of Japan based on the regulation of sleep-wake rhythms and enhancement of the quality of sleep